Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Nat Med. 2022; online ahead of print DOI: 10.1038/s41591-022-01971-4
This pooled analysis of DAPA-HF and DELIVER was planned to provide a more robust estimate of the effect of dapagliflozin on outcomes that the individual trials had limited power to assess. In addition, the meta-analysis aimed to address the findings of a pooled analysis of the EMPEROR trials with empagliflozin, which appeared to show that the size of the risk reduction of HF admissions declined as LVEF increased.
In the meta-analysis of the DAPA-HF and DELIVER trials, dapagliflozin reduced the risk of each of the prespecified endpoints, namely death from CV causes, death from any cause, total hospital admissions for HF and major adverse cardiovascular events in patients with HF, with no evidence of heterogeneity across the range of ejection fractions.